<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03977727</url>
  </required_header>
  <id_info>
    <org_study_id>U1111-1213-9104</org_study_id>
    <nct_id>NCT03977727</nct_id>
  </id_info>
  <brief_title>FIasp® vs. Novolog® in Type 1 Diabetics Using 670G Medtronic Pump</brief_title>
  <official_title>An Exploratory, Single-center, Randomized, Open Label, Active-control, Cross-over Trial Comparing the Efficacy and Safety of Continuous Subcutaneous Insulin Infusion of Faster-acting Insulin Aspart (Fiasp®) Compared to NovoLog® Used in the Medtronic 670G Closed Loop System in Adults With Type 1 Diabetes</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Texas Diabetes &amp; Endocrinology, P.A.</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Texas Diabetes &amp; Endocrinology, P.A.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>Yes</is_fda_regulated_device>
    <is_us_export>Yes</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an exploratory, single-center, randomized, open label, active-controlled, complete&#xD;
      cross-over trial comparing safety and efficacy of Fiasp® versus NovoLog® when used in the&#xD;
      Medtronic MiniMed 670G system in subjects with T1DM.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being performed to compare Fiasp® in terms of glycemic control with a focus on&#xD;
      post-prandial 1-hour plasma glucose level and system-based outcomes to NovoLog® insulin when&#xD;
      used in the Medtronic mini Med 670G HCL system (operating in auto-mode) in patients with type&#xD;
      1 diabetes. The investigator's hypothesis is that post prandial glucoses will be lower and&#xD;
      time in range will be greater during the Fiasp® treatment period.&#xD;
&#xD;
      Subjects will have a 2 week screening period, 14 week treatment period and 30 Day follow up&#xD;
      period. After at least 7 weeks on treatment period one they will crossover to treatment&#xD;
      period two on the opposite treatment for 7 additional weeks.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">June 11, 2019</start_date>
  <completion_date type="Actual">April 20, 2020</completion_date>
  <primary_completion_date type="Actual">March 9, 2020</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>1-Hour Change in Postprandial Plasma Glucose (PPG)</measure>
    <time_frame>6th week of therapy</time_frame>
    <description>Change was calculated as the PPG value at 1 hour minus the PPG value at baseline (time -2 minutes) during meal test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>2-Hour Change in Postprandial Plasma Glucose (PPG)</measure>
    <time_frame>6th week of therapy</time_frame>
    <description>Change was calculated as the value at 2 hour minus the value at baseline during meal test</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent Between Below 70 mg/dL</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent Between 70 mg/dL and 180 mg/dL</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent Above 200 mg/dL</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent in Hypoglycemia (40 mg/dL - 54 mg/dL)</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of Time Spent in Severe Hypoglycemia (&gt; 40 mg/dL)</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>1,5 Anhydroglucitol Levels</measure>
    <time_frame>Week 6, Week 13</time_frame>
    <description>1,5 anhydroglucitol levels were measured on the 6th week of each therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Fructosamine Levels</measure>
    <time_frame>Week 6, Week 13</time_frame>
    <description>Cumulative glycemic control expressed in fructosamine levels (micromol/Liter) were measured on the 6th week of each therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>HbA1c</measure>
    <time_frame>Week 6, Week 13</time_frame>
    <description>Cumulative glycemic control expressed in HbA1c% measured on the 6th week of each therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Use - Change in Daily Dose</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Change was calculated as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Use - Bolus</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Change in %bolus insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Use - Basal</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Change in %basal insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Use - Automatic Basal Insulin</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Average amount per day (units) calculated for each participant under each therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Pump - Active Insulin Time</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Average time per day (hours) calculated for each participant under each therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Pump - Auto Mode</measure>
    <time_frame>Weeks 3 through 6, Weeks 10 through 13</time_frame>
    <description>Percentage of time spent in auto-mode after calibration under each therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Insulin Pump - Manual Mode</measure>
    <time_frame>Weeks 3 through 6, Weeks 10 through 13</time_frame>
    <description>Percentage of time spent in manual-mode after calibration under each therapy</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Carbohydrate Ratio</measure>
    <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
    <description>Change was calculated as the carbohydrate ratio on the last day of therapy minus the carbohydrate ratio on the 1st day of therapy in each period</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Infusion Site Reactions</measure>
    <time_frame>14 week treatment period</time_frame>
    <description>Number of Infusion site reactions reported by patient</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pump Occlusions</measure>
    <time_frame>14 week treatment period</time_frame>
    <description>Number of Occlusion events reported by patient</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Type 1 Diabetes Mellitus</condition>
  <arm_group>
    <arm_group_label>Fiasp/Novolog</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Novolog/Fiasp</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fiasp®</intervention_name>
    <description>Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system</description>
    <arm_group_label>Fiasp/Novolog</arm_group_label>
    <arm_group_label>Novolog/Fiasp</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Novolog®</intervention_name>
    <description>Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system</description>
    <arm_group_label>Fiasp/Novolog</arm_group_label>
    <arm_group_label>Novolog/Fiasp</arm_group_label>
    <other_name>Aspart</other_name>
  </intervention>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>670G hybrid closed loop continuous subcutaneous insulin infusion system</intervention_name>
    <description>CSII</description>
    <arm_group_label>Fiasp/Novolog</arm_group_label>
    <arm_group_label>Novolog/Fiasp</arm_group_label>
    <other_name>Medtronic 670G pump</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Informed consent obtained before any trial-related activities. Trial-related&#xD;
             activities are any procedures that are carried out as part of the trial, including&#xD;
             activities to determine suitability for the trial&#xD;
&#xD;
          2. Male or female, age ≥18 years at the time of signing informed consent&#xD;
&#xD;
          3. Documented diagnoses of T1DM ≥1 year prior to the day of screening&#xD;
&#xD;
          4. Using the Medtronic pump Minimed 670G for CSII in a basal-bolus regimen with a rapid&#xD;
             acting insulin analogue for at least 30 days prior to screening and willing to&#xD;
             continue using their personal Medtronic Minimed 670G and CSII for insulin treatment&#xD;
             throughout the trial.&#xD;
&#xD;
          5. Ability and willingness to use the same insulin infusion sets throughout the trial&#xD;
&#xD;
          6. Using the same insulin for at least 30 days prior to screening&#xD;
&#xD;
          7. HbA1c &lt; 8.5% as assessed by local laboratory at screening&#xD;
&#xD;
          8. BMI ≤ 35.0 kg/m2 at screening&#xD;
&#xD;
          9. Ability and willingness to adhere to the protocol including performing SMPG profiles,&#xD;
             attending visits, utilizing the auto mode feature of the pump for at least 80 % of the&#xD;
             time during the study, and completing meal tests&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Known or suspected hypersensitivity to trial products or related products&#xD;
&#xD;
          2. Female who is pregnant, breast-feeding or intends to become pregnant or is of&#xD;
             child-bearing potential and not using adequate contraceptive methods (adequate&#xD;
             contraceptive measures as required by local regulation or practice)&#xD;
&#xD;
          3. Participation in another clinical trial within 28 days before the screening visit.&#xD;
             Note: clinical trials do not include non-interventional studies&#xD;
&#xD;
          4. Anticipated significant change in lifestyle (e.g. eating, exercise or sleeping&#xD;
             pattern) throughout the trial&#xD;
&#xD;
          5. Any of the following: myocardial infarction, stroke, hospitalization for unstable&#xD;
             angina or transient ischemic attack within the past 180 days prior to the day of&#xD;
             screening&#xD;
&#xD;
          6. Subjects classified as being in New York Heart Association (NYHA) Class IV at&#xD;
             screening&#xD;
&#xD;
          7. Planned coronary, carotid or peripheral artery revascularization known on the day of&#xD;
             screening.&#xD;
&#xD;
          8. Inadequately treated blood pressure defined as Grade 3 hypertension or higher&#xD;
             (Systolic&#xD;
&#xD;
             ≥180 mmHg or diastolic ≥110 mmHg) at screening&#xD;
&#xD;
          9. Impaired liver function, defined as ALT ≥ 2.5 times upper normal limit at screening&#xD;
&#xD;
         10. Renal impairment measured as estimated Glomerular Filtration Rate (eGFR) value of &lt; 45&#xD;
             ml/min/1.73 m2&#xD;
&#xD;
         11. Anticipated initiation or change in concomitant medications (for more than 14&#xD;
             consecutive days) known to affect weight or glucose metabolism in the opinion of the&#xD;
             Investigator&#xD;
&#xD;
         12. Proliferative retinopathy or maculopathy requiring acute treatment at the time of&#xD;
             screening&#xD;
&#xD;
         13. History of hospitalization for ketoacidosis ≤180 days prior to the day of screening&#xD;
&#xD;
         14. Treatment with any medication for the indication of diabetes or obesity other than&#xD;
             stated in the inclusion criteria within 30 days before screening&#xD;
&#xD;
         15. Presence of malignant neoplasms at the time of screening. Basal and squamous cell skin&#xD;
             cancer and any carcinoma in-situ is allowed.&#xD;
&#xD;
         16. Reoccurring Severe hypoglycemia while on the Medtronic Minimed 670G in the&#xD;
             investigators opinion&#xD;
&#xD;
         17. Any condition which, in the opinion of the Investigator, might jeopardize Subject's&#xD;
             safety or compliance with the protocol&#xD;
&#xD;
             -&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Thomas Blevins, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Texas Diabetes &amp; Endocrinology</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Texas Diabetes &amp; Endocrinology</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78731</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>June 4, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">June 6, 2019</study_first_posted>
  <results_first_submitted>June 1, 2020</results_first_submitted>
  <results_first_submitted_qc>August 20, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">September 9, 2020</results_first_posted>
  <last_update_submitted>September 9, 2020</last_update_submitted>
  <last_update_submitted_qc>September 9, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 29, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Texas Diabetes &amp; Endocrinology, P.A.</investigator_affiliation>
    <investigator_full_name>Thomas C. Blevins, M.D.</investigator_full_name>
    <investigator_title>PI</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Diabetes Mellitus, Type 1</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Insulin Aspart</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>April 16, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/27/NCT03977727/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <recruitment_details>45 patients were screened for eligibility between June 11,2019 and November 21, 2019 at a diabetes clinic in Austin, TX</recruitment_details>
      <pre_assignment_details>40 of 45 participants were randomized. All 5 who were not randomized did not meet inclusion criteria.</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Fiasp/Novolog</title>
          <description>7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion&#xD;
Fiasp®: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
Novolog®: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
670G hybrid closed loop continuous subcutaneous insulin infusion system: CSII</description>
        </group>
        <group group_id="P2">
          <title>Novolog/Fiasp</title>
          <description>7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion&#xD;
Fiasp®: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
Novolog®: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
670G hybrid closed loop continuous subcutaneous insulin infusion system: CSII</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>First Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>Received Treatment</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
        <period>
          <title>Second Treatment</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="20"/>
                <participants group_id="P2" count="17"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Lost to Follow-up</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="3"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Fiasp/Novolog</title>
          <description>7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion&#xD;
Fiasp®: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
Novolog®: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
670G hybrid closed loop continuous subcutaneous insulin infusion system: CSII</description>
        </group>
        <group group_id="B2">
          <title>Novolog/Fiasp</title>
          <description>7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion&#xD;
Fiasp®: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
Novolog®: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
670G hybrid closed loop continuous subcutaneous insulin infusion system: CSII</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="20"/>
            <count group_id="B2" value="17"/>
            <count group_id="B3" value="37"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="47.2" spread="13.17"/>
                    <measurement group_id="B2" value="43.8" spread="12.77"/>
                    <measurement group_id="B3" value="45.7" spread="27.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="12"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="2"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="19"/>
                    <measurement group_id="B2" value="16"/>
                    <measurement group_id="B3" value="35"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="20"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="37"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>BMI</title>
          <units>kg/m^2</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.9" spread="3.69"/>
                    <measurement group_id="B2" value="27.3" spread="3.15"/>
                    <measurement group_id="B3" value="27.1" spread="3.41"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Weight</title>
          <units>kg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="80.3" spread="14.7"/>
                    <measurement group_id="B2" value="83.3" spread="12.45"/>
                    <measurement group_id="B3" value="81.7" spread="13.61"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Height</title>
          <units>cm</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="172.3" spread="10.82"/>
                    <measurement group_id="B2" value="174.6" spread="7.22"/>
                    <measurement group_id="B3" value="173.4" spread="9.29"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>1-Hour Change in Postprandial Plasma Glucose (PPG)</title>
        <description>Change was calculated as the PPG value at 1 hour minus the PPG value at baseline (time -2 minutes) during meal test</description>
        <time_frame>6th week of therapy</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>1-Hour Change in Postprandial Plasma Glucose (PPG)</title>
          <description>Change was calculated as the PPG value at 1 hour minus the PPG value at baseline (time -2 minutes) during meal test</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="105.15" spread="56.73"/>
                    <measurement group_id="O2" value="154.24" spread="54.25"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="99.90" spread="82.70"/>
                    <measurement group_id="O2" value="114.94" spread="61.14"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed model was fit with therapy (Fiasp vs. NovoLog), period (Period 1 vs Period 2), and sequence (Fiasp/NovoLog vs NovoLog/Fiasp) as fixed effects. Subjects included as random effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.008</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>27.35</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>7.88</ci_lower_limit>
            <ci_upper_limit>48.4</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>2-Hour Change in Postprandial Plasma Glucose (PPG)</title>
        <description>Change was calculated as the value at 2 hour minus the value at baseline during meal test</description>
        <time_frame>6th week of therapy</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>2-Hour Change in Postprandial Plasma Glucose (PPG)</title>
          <description>Change was calculated as the value at 2 hour minus the value at baseline during meal test</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>mg/dL</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="72.55" spread="90.62"/>
                    <measurement group_id="O2" value="65.00" spread="57.22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="69.10" spread="92.55"/>
                    <measurement group_id="O2" value="104.53" spread="80.57"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed model was fit with therapy (Fiasp vs. NovoLog), period (Period 1 vs Period 2), and sequence (Fiasp/NovoLog vs NovoLog/Fiasp) as fixed effects. Subjects included as random effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.136</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>15.22</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-5.42</ci_lower_limit>
            <ci_upper_limit>39.46</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent Between Below 70 mg/dL</title>
        <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent Between Below 70 mg/dL</title>
          <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
          <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.94" spread="1.48"/>
                    <measurement group_id="O2" value="1.72" spread="1.20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.42" spread="1.62"/>
                    <measurement group_id="O2" value="2.03" spread="1.36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed model was fit with therapy (Fiasp vs. NovoLog), period (Period 1 vs Period 2), and sequence (Fiasp/NovoLog vs NovoLog/Fiasp) as fixed effects. Subjects included as random effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.029</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>.4</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.05</ci_lower_limit>
            <ci_upper_limit>.73</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent Between 70 mg/dL and 180 mg/dL</title>
        <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent Between 70 mg/dL and 180 mg/dL</title>
          <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
          <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="74.80" spread="8.08"/>
                    <measurement group_id="O2" value="73.67" spread="6.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="70.28" spread="8.12"/>
                    <measurement group_id="O2" value="75.04" spread="5.95"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed model was fit with therapy (Fiasp vs. NovoLog), period (Period 1 vs Period 2), and sequence (Fiasp/NovoLog vs NovoLog/Fiasp) as fixed effects. Subjects included as random effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.016</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.81</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-2.84</ci_lower_limit>
            <ci_upper_limit>-0.31</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent Above 200 mg/dL</title>
        <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent Above 200 mg/dL</title>
          <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
          <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="14.90" spread="6.90"/>
                    <measurement group_id="O2" value="15.44" spread="5.65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="18.57" spread="7.85"/>
                    <measurement group_id="O2" value="14.11" spread="4.43"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed model was fit with therapy (Fiasp vs. NovoLog), period (Period 1 vs Period 2), and sequence (Fiasp/NovoLog vs NovoLog/Fiasp) as fixed effects. Subjects included as random effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.045</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>1.38</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>.04</ci_lower_limit>
            <ci_upper_limit>2.32</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent in Hypoglycemia (40 mg/dL - 54 mg/dL)</title>
        <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent in Hypoglycemia (40 mg/dL - 54 mg/dL)</title>
          <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
          <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".46" spread=".53"/>
                    <measurement group_id="O2" value=".40" spread=".48"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".50" spread=".50"/>
                    <measurement group_id="O2" value=".35" spread=".36"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Percentage of Time Spent in Severe Hypoglycemia (&gt; 40 mg/dL)</title>
        <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Time Spent in Severe Hypoglycemia (&gt; 40 mg/dL)</title>
          <description>Percent of time spent is calculated as the accumulated time in hours spent within each range divided by the total number of hours spent under therapy with each drug (6 weeks each)</description>
          <population>All patients for whom continuous glucose monitoring data was available during the specified time periods</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0" spread="0"/>
                    <measurement group_id="O2" value="0" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>1,5 Anhydroglucitol Levels</title>
        <description>1,5 anhydroglucitol levels were measured on the 6th week of each therapy</description>
        <time_frame>Week 6, Week 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each period</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>1,5 Anhydroglucitol Levels</title>
          <description>1,5 anhydroglucitol levels were measured on the 6th week of each therapy</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each period</population>
          <units>µg/mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.50" spread="3.37"/>
                    <measurement group_id="O2" value="7.12" spread="3.23"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.28" spread="3.54"/>
                    <measurement group_id="O2" value="6.95" spread="3.31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed model was fit with therapy (Fiasp vs. NovoLog), period (Period 1 vs Period 2), and sequence (Fiasp/NovoLog vs NovoLog/Fiasp) as fixed effects. Subjects included as random effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.303</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-.2</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.59</ci_lower_limit>
            <ci_upper_limit>.16</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Fructosamine Levels</title>
        <description>Cumulative glycemic control expressed in fructosamine levels (micromol/Liter) were measured on the 6th week of each therapy</description>
        <time_frame>Week 6, Week 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each period</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Fructosamine Levels</title>
          <description>Cumulative glycemic control expressed in fructosamine levels (micromol/Liter) were measured on the 6th week of each therapy</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each period</population>
          <units>mcmol/L</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="322.60" spread="42.24"/>
                    <measurement group_id="O2" value="296.35" spread="31.10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="305.40" spread="32.28"/>
                    <measurement group_id="O2" value="314.31" spread="28.97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed model was fit with therapy (Fiasp vs. NovoLog), period (Period 1 vs Period 2), and sequence (Fiasp/NovoLog vs NovoLog/Fiasp) as fixed effects. Subjects included as random effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.968</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-1.18</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-10.32</ci_lower_limit>
            <ci_upper_limit>9.99</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>HbA1c</title>
        <description>Cumulative glycemic control expressed in HbA1c% measured on the 6th week of each therapy</description>
        <time_frame>Week 6, Week 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each period</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>HbA1c</title>
          <description>Cumulative glycemic control expressed in HbA1c% measured on the 6th week of each therapy</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each period</population>
          <units>HbA1c%</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.09" spread=".47"/>
                    <measurement group_id="O2" value="7.00" spread=".31"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7.09" spread=".44"/>
                    <measurement group_id="O2" value="6.88" spread=".33"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Linear mixed model was fit with therapy (Fiasp vs. NovoLog), period (Period 1 vs Period 2), and sequence (Fiasp/NovoLog vs NovoLog/Fiasp) as fixed effects. Subjects included as random effects.</groups_desc>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>.059</p_value>
            <method>Mixed Models Analysis</method>
            <param_type>Mean Difference (Final Values)</param_type>
            <param_value>-.06</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>-.13</ci_lower_limit>
            <ci_upper_limit>0</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Use - Change in Daily Dose</title>
        <description>Change was calculated as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Use - Change in Daily Dose</title>
          <description>Change was calculated as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.1" spread="7.45"/>
                    <measurement group_id="O2" value=".29" spread="13.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.10" spread="11.80"/>
                    <measurement group_id="O2" value="-2.65" spread="9.13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Use - Bolus</title>
        <description>Change in %bolus insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Use - Bolus</title>
          <description>Change in %bolus insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>percentage of units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.54" spread="6.54"/>
                    <measurement group_id="O2" value="-4.32" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.83" spread="7.62"/>
                    <measurement group_id="O2" value="-1.34" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Use - Basal</title>
        <description>Change in %basal insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Use - Basal</title>
          <description>Change in %basal insulin (units) as the value on the last day of therapy minus the value on the 1st day of therapy in each period</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>percentage of units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.54" spread="6.54"/>
                    <measurement group_id="O2" value="4.32" spread="7.85"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.83" spread="7.62"/>
                    <measurement group_id="O2" value="1.34" spread="5.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Use - Automatic Basal Insulin</title>
        <description>Average amount per day (units) calculated for each participant under each therapy</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Use - Automatic Basal Insulin</title>
          <description>Average amount per day (units) calculated for each participant under each therapy</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>units</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".87" spread=".307"/>
                    <measurement group_id="O2" value="1.20" spread=".65"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value=".86" spread=".32"/>
                    <measurement group_id="O2" value="1.20" spread=".66"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Pump - Active Insulin Time</title>
        <description>Average time per day (hours) calculated for each participant under each therapy</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Pump - Active Insulin Time</title>
          <description>Average time per day (hours) calculated for each participant under each therapy</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>hours</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread=".06"/>
                    <measurement group_id="O2" value="3" spread="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3" spread="0"/>
                    <measurement group_id="O2" value="3" spread=".02"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Pump - Auto Mode</title>
        <description>Percentage of time spent in auto-mode after calibration under each therapy</description>
        <time_frame>Weeks 3 through 6, Weeks 10 through 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Pump - Auto Mode</title>
          <description>Percentage of time spent in auto-mode after calibration under each therapy</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="89.28" spread="6.42"/>
                    <measurement group_id="O2" value="89.31" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="86.17" spread="11.43"/>
                    <measurement group_id="O2" value="87.2" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Insulin Pump - Manual Mode</title>
        <description>Percentage of time spent in manual-mode after calibration under each therapy</description>
        <time_frame>Weeks 3 through 6, Weeks 10 through 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Insulin Pump - Manual Mode</title>
          <description>Percentage of time spent in manual-mode after calibration under each therapy</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>percentage of time</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.72" spread="6.42"/>
                    <measurement group_id="O2" value="10.69" spread="8.42"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.45" spread="11.44"/>
                    <measurement group_id="O2" value="12.8" spread="15.6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Carbohydrate Ratio</title>
        <description>Change was calculated as the carbohydrate ratio on the last day of therapy minus the carbohydrate ratio on the 1st day of therapy in each period</description>
        <time_frame>Weeks 1 through 6, Weeks 8 through 13</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Carbohydrate Ratio</title>
          <description>Change was calculated as the carbohydrate ratio on the last day of therapy minus the carbohydrate ratio on the 1st day of therapy in each period</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>I:CR</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.27" spread="1.09"/>
                    <measurement group_id="O2" value="-.02" spread=".47"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-.14" spread=".95"/>
                    <measurement group_id="O2" value=".2" spread=".76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Infusion Site Reactions</title>
        <description>Number of Infusion site reactions reported by patient</description>
        <time_frame>14 week treatment period</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Infusion Site Reactions</title>
          <description>Number of Infusion site reactions reported by patient</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>occurances</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                    <measurement group_id="O2" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                    <measurement group_id="O2" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Pump Occlusions</title>
        <description>Number of Occlusion events reported by patient</description>
        <time_frame>14 week treatment period</time_frame>
        <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
        <group_list>
          <group group_id="O1">
            <title>Fiasp/Novolog</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Fiasp® then crossed over to 6 weeks on Novolog®</description>
          </group>
          <group group_id="O2">
            <title>Novolog/Fiasp</title>
            <description>Participants with type 1 diabetes spent 6 weeks on Novolog® then crossed over to 6 weeks on Fiasp®</description>
          </group>
        </group_list>
        <measure>
          <title>Pump Occlusions</title>
          <description>Number of Occlusion events reported by patient</description>
          <population>All patients who participated in the meal test after 6 weeks of therapy in each arm</population>
          <units>occurances</units>
          <param>Number</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="17"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Fiasp</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>NovoLog</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="7"/>
                    <measurement group_id="O2" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Approximately 20 weeks. The entire duration of the subjects study period.</time_frame>
      <desc>Adverse event information was collected at all phone or office visits during the trial.</desc>
      <group_list>
        <group group_id="E1">
          <title>Fiasp/Novolog</title>
          <description>7 weeks on Fiasp® then crossover to 7 weeks on Novolog® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion&#xD;
Fiasp®: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
Novolog®: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
670G hybrid closed loop continuous subcutaneous insulin infusion system: CSII</description>
        </group>
        <group group_id="E2">
          <title>Novolog/Fiasp</title>
          <description>7 weeks on Novolog® then crossover to 7 weeks on Fiasp® in subjects on the 670g Hybrid Closed Loop Continuous Subcutaneous Insulin Infusion&#xD;
Fiasp®: Fiasp® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
Novolog®: Novolog® used in a 670G hybrid closed loop continuous subcutaneous insulin infusion system&#xD;
670G hybrid closed loop continuous subcutaneous insulin infusion system: CSII</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Herniated Disc</sub_title>
                <description>Subject hospitalized for laminectomy to repair herniated disc</description>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="11" subjects_at_risk="19"/>
                <counts group_id="E2" subjects_affected="7" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Trivial tricuspid regurgitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="18" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Trivial mitral regurgitation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>First Degree AV Block</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Intermittent Heart Palpitations</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Intermittent bradycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Worsening of Hypertension</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Supraventricular Tachycardia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hyperkalemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Endocrine disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of hypocalcemia</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Worsening of hypothyroidsm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Eye disorders</title>
            <event_list>
              <event>
                <sub_title>Non Proliferative Diabetic Retinopathy</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Center involved diabetic macular edema (right eye)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Gasteroenteritis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Traveler's Diarrhea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Hiatial Hernia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Gastroesophageal reflux disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nausea</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Worsening of Seasonal Allergic Rhinitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sore Throat</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Nasal Congestion</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Fever</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Abdominal Cramps</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Emesis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Ecchymosis (bilateral hands)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Vasovagal Syncope</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Influenza</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Viral infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Conjuntivitis</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Common Cold</sub_title>
                <counts group_id="E1" events="3" subjects_affected="2" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Sinus Infection</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Headache</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Herniated Disc</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Back pain</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Right index finger dislocation</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Triangular fibrocartilage band tear (left wrist)</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>myalgia (bilateral shoulders0</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Product Issues</title>
            <event_list>
              <event>
                <sub_title>Irritation at Infusion site (abdoment)</sub_title>
                <description>related to infusion site , not insulin</description>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>acute kidney injury</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Bronchitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Redness at infusion site (right abdomen)</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>Right Thumb laceration</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="18"/>
              </event>
              <event>
                <sub_title>erythema at infusion site</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="19"/>
                <counts group_id="E2" events="1" subjects_affected="1" subjects_at_risk="18"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Thomas Blevins, MD</name_or_title>
      <organization>Texas Diabetes &amp; Endocrinology</organization>
      <phone>512-334-3505 ext 1</phone>
      <email>blevins@texasdiabetes.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

